Janssen registers Phase 3 esketamine nasal spray trial for treatment-resistant depression
A new Phase 3 record for Janssen's esketamine nasal spray joins this week's previously reported robotic-assisted knee replacement trial in the registry roundup.
Two trials mark this week's registry activity, one newly posted and one carried over from last week.
- **Esketamine Nasal Spray vs Placebo in Treatment-Resistant Depression (NCT07716098)**: This is a Phase 3, recruiting trial sponsored by Janssen Research & Development, LLC. The study will test how well each individual dose of esketamine (56 milligrams and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression1, with enrollment estimated at 348 participants and a primary completion date estimated for 2028-12-27.
- **Robotic-Assisted vs Conventional Total Knee Arthroplasty with Virtual Home-Based Rehabilitation (NCT07716267)**: This not yet recruiting trial remains sponsored by Mark Hurworth, with Curtin University and Johnson & Johnson Medical Companies as collaborators. The study is a prospective, single-centre, parallel-group randomised controlled trial conducted at St John of God Murdoch Hospital in Western Australia, with approximately 60 adults undergoing primary TKA for radiographically confirmed knee osteoarthritis to be randomly allocated in a 1:1 ratio to receive either robotic-assisted or conventional surgery2, with an estimated primary completion date of 2028-12.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.